Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ONFI vs PROKETAZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.
Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.
Treatment of seizures associated with Lennox-Gastaut syndrome,Adjunctive therapy for other seizure types
Nausea and vomiting,Antipsychotic (off-label),Sedation (off-label)
Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.
25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.
The terminal elimination half-life of clobazam is 36–42 hours. The active metabolite N-desmethylclobazam has a half-life of 71–82 hours. The long half-life permits once-daily dosing but also leads to slow accumulation; steady-state is achieved after 2–3 weeks.
Terminal elimination half-life is 15-20 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Hepatic via CYP3A4 and CYP2C19; primary metabolite N-desmethylclobazam is active.
Hepatic via CYP2D6 and other cytochrome P450 enzymes.
Clobazam (ONFI) undergoes extensive hepatic metabolism. Approximately 82% of the dose is eliminated in urine (as unchanged drug and metabolites) and about 11% in feces. Unchanged clobazam accounts for <1% of urinary excretion. The major metabolite, N-desmethylclobazam, is excreted primarily renally.
Primarily renal excretion of metabolites; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 20% of total clearance.
Clobazam is approximately 80–90% bound to plasma proteins, primarily albumin.
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution is approximately 100 L (range 77–120 L), or roughly 1.4 L/kg. This large Vd indicates extensive tissue distribution and accumulation in fatty tissues.
Volume of distribution is 20-30 L/kg, indicating extensive tissue distribution and high lipophilicity.
Oral bioavailability is nearly complete (>90%). Clobazam is well absorbed after oral administration with only minor first-pass metabolism.
Oral bioavailability is 30-40% due to extensive first-pass metabolism. IM bioavailability is approximately 70%.
No specific GFR-based dose adjustments; use with caution in severe impairment (Cr Cl < 30 m L/min) due to potential for increased sedation.
GFR 30-50 m L/min: reduce dose by 25%; GFR <30 m L/min: reduce dose by 50% and extend interval to every 12 hours.
Mild to moderate (Child-Pugh A/B): Initial 5 mg orally twice daily; may increase by 5 mg/day after 1 week to maximum 20 mg/day. Severe (Child-Pugh C): Not recommended.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Clobazam (ONFI) for seizures: Age 2 to <6 years, body weight ≥12.5 kg: Initial 5 mg orally once daily; titrate to maintenance 5 mg twice daily. Age ≥6 years: Weight ≤30 kg: Initial 5 mg once daily; titrate to 5 mg twice daily (max 20 mg/day). Weight >30 kg: same as adult dosing. Administer with food.
0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 50 mg per day for children <12 years.
Elderly (≥65 years): Initial 5 mg orally twice daily; increase slowly to lowest effective maintenance due to increased sensitivity and risk of falls. Avoid doses above 20 mg/day unless clearly necessary.
Initial dose 12.5 mg intramuscularly; maximum 50 mg per day; monitor for anticholinergic effects and sedation.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients for whom alternative treatment options are inadequate.
Increased risk of death in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis.
Risk of respiratory depression, especially with opioids,Sedation and somnolence,Risk of abuse and dependence,Withdrawal seizures on abrupt discontinuation,Increased risk of suicidal thoughts or behavior
May cause QT prolongation, neuroleptic malignant syndrome, tardive dyskinesia, hypotension, and increased risk of falls. Use with caution in patients with cardiovascular disease, seizures, or hepatic impairment.
Hypersensitivity to clobazam or any component of formulation,Severe hepatic impairment
Hypersensitivity to phenothiazines, severe CNS depression, comatose states, and blood dyscrasias.
Avoid grapefruit and grapefruit juice as they may increase clobazam levels. No other significant food interactions are known. CNS depressant effects may be potentiated by alcohol.
Avoid grapefruit juice as it may inhibit metabolism and increase toxicity. Avoid high-tyramine foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis if used with MAOIs.
Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia, poor feeding, respiratory depression, and hypothermia; consistent exposure may cause floppy infant syndrome. Late pregnancy exposure linked to neonatal benzodiazepine withdrawal syndrome.
PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third trimesters: Possible extrapyramidal symptoms and neonatal withdrawal in newborns after maternal use near term. Use only if benefit outweighs risk.
Clobazam is excreted into breast milk; M/P ratio approximately 0.5-0.6. Accumulation possible in neonates; monitor for sedation, poor feeding, apnea. Avoid if infant has impaired hepatic function or low birth weight. American Academy of Pediatrics recommends caution; use lowest effective maternal dose.
Prochlorperazine is excreted into human breast milk in low amounts. Milk/plasma (M/P) ratio is approximately 1.0. Potential for adverse effects in nursing infants, including sedation and extrapyramidal symptoms. Caution advised; monitor infant for drowsiness and EPS.
Increased clearance during pregnancy (CYP3A4 induction); plasma concentrations may decrease by 30-50% in third trimester. Dose adjustments often required: monitor therapeutic response and consider dose increase by 50-100% in late pregnancy; postpartum reduce to prepregnancy dose over 1-2 weeks to avoid toxicity.
Pregnancy may increase clearance of prochlorperazine due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed; consider lower initial doses and titrate based on clinical response. No specific pharmacokinetic data in pregnancy; use minimum effective dose.
ONFI (clobazam) is a benzodiazepine indicated for seizures associated with Lennox-Gastaut syndrome. Titrate slowly to minimize sedation. Monitor for withdrawal symptoms upon discontinuation; taper over several weeks. Not recommended for use in patients with severe hepatic impairment (Child-Pugh C). For patients on other CNS depressants, consider dose reduction. Clobazam's active metabolite, N-desmethylclobazam, has a long half-life (36-46 hours) and can accumulate, especially in poor CYP2C19 metabolizers. In such patients, consider lower doses and monitor for excessive sedation.
Monitor for extrapyramidal symptoms, especially in elderly and pediatric patients. Proketazine may cause significant hypotension; avoid rapid IV administration. Contraindicated in patients with bone marrow suppression or severe hepatic impairment.
Take ONFI exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Avoid alcohol and other sedatives while taking this medication due to increased risk of drowsiness and respiratory depression.,Report any unusual mood changes, depression, or suicidal thoughts to your healthcare provider.,Do not drive or operate heavy machinery until you know how ONFI affects you, as it can cause dizziness and drowsiness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using ONFI.,Store at room temperature, away from moisture and heat.
Avoid alcohol and CNS depressants as they may increase sedation.,Report any involuntary muscle movements or stiffness immediately.,Rise slowly from sitting or lying to prevent dizziness.,May cause dry mouth; use sugar-free gum or candy.,Do not discontinue abruptly without consulting prescriber.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ONFI vs PROKETAZINE, answered by our medical review team.
ONFI is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.. PROKETAZINE is a Phenothiazine Antipsychotic that works by Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ONFI and PROKETAZINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ONFI is: Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.. The standard adult dose of PROKETAZINE is: 25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ONFI and PROKETAZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ONFI is classified as Category C. Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia. PROKETAZINE is classified as Category C. PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.